Dare Bioscience
DARE
40 hedge funds and large institutions have $9.89M invested in Dare Bioscience in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 10 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
5% more funds holding
Funds holding: 38 → 40 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.03% less ownership
Funds ownership: 0.75% → 0.72% (-0.03%)
28% less capital invested
Capital invested by funds: $13.7M → $9.89M (-$3.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$625K |
| 2 |
SAM
Soviero Asset Management
New York
|
+$473K |
| 3 |
Millennium Management
New York
|
+$403K |
| 4 |
BlackRock
New York
|
+$369K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$340K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$2.07M |
| 2 |
Goldman Sachs
New York
|
-$493K |
| 3 |
Two Sigma Investments
New York
|
-$310K |
| 4 |
FFS
Founders Financial Securities
Towson,
Maryland
|
-$207K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$155K |
DARE Hedge Fund Activity: Q1 2022 in Review
40 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q1 2022, worth a combined $9.89M — down 28% from $13.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DARE positions and 10 closed out — a net gain of 2 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $625K. The largest seller was Marshall Wace, cutting an estimated $2.07M.
- 40 institutional investors held Dare Bioscience (DARE) as of Q1 2022, up from 38 in Q4 2021.
- Funds reported $9.89M of Dare Bioscience stock for Q1 2022, down 28% quarter-over-quarter.
- 12 funds opened new Dare Bioscience positions in Q1 2022 and 10 closed out, a net change of +2 holders.
- The largest Dare Bioscience buyer in Q1 2022 was Vanguard Group, an estimated $625K added.
- The largest Dare Bioscience seller in Q1 2022 was Marshall Wace, an estimated $2.07M sold.
Based on aggregated 13F filings for Q1 2022.